Skip to content

Accuracy of Coplanar Template Assistance for Pelvic and Groin Areas Biopsy

A Prospective Study on Accuracy and Safety of Coplanar Template Assisted CT-guided Pelvic and Groin Areas Biopsy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05419141
Enrollment
30
Registered
2022-06-15
Start date
2022-06-20
Completion date
2024-06-20
Last updated
2022-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic and Groin Areas Biopsy

Keywords

Pelvic, Groin, Biopsy, Coplanar template.

Brief summary

In recent years, template guidance has been applied and developed in the field of puncture related operations, such as template-assisted radioactive seed implantation. With the guidance of template, needle pathway of seed implantation, biopsy and fiducial marker implantation can be precisely planned , which is conducive to accurate proceeding. Templates can be divided into coplanar templates and non-coplanar templates. The digital coplanar template coordinate puncture system has been developed in China and has been applied in clinical practice. In our previous studies, coplanar template assisted CT-guided radioactive seed implantation has good clinical feasibility for percutaneous biopsy of small pulmonary nodules. However, the accuracy of coplanar template assistance for abdominal tumor puncture are lacking in prospective studies. The study aims to prospectively observe the accuracy and safety of coplanar template assisted CT-guided Pelvic and Groin Areas biopsy.

Interventions

None listed

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years

Inclusion criteria

1. Ages 18 to 90 2. Single or multiple Pelvic and Groin Areas mass (solid, partially solid) 3. Without taking drugs affecting coagulation and/or platelet aggregation are used; If used, the drug has been discontinued for a sufficient period of time (e.g. 1 week) \- Page 3 of 4 \[DRAFT\] - 4. KPS\>60 points, no serious or uncontrolled underlying diseases, clinical evaluation patients can tolerate puncture 5. Planned biopsy with applicable puncture path 6. With informed consent.

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of Depthduring the operationDepth (millimeter) difference between actual puncture and planned puncture pathway
Accuracy of Angleduring the operationAngle (degree) difference between actual puncture and planned puncture pathway

Secondary

MeasureTime frameDescription
Success rate of needle punctureduring the operationSuccess rate of needle puncture
Complication rateperioperative the operationsuch as pneumoperitoneum, subcutaneous emphysema, hemorrhage, infection, etc.
operating durationduring the operationoperating duration from the starting to the ending
Number of CT scansduring the operationNumber of CT scans

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026